CTOs on the Move

Synspira

www.synspira.com

 
Synspira Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with cystic fibrosis (CF) and other rare diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.synspira.com
  • 10 Speen St, 302
    Framingham, MA USA 01701
  • Phone: 617.466.3111

Executives

Name Title Contact Details

Funding

Synspira raised $14M on 10/20/2020

Similar Companies

Jazz Pharmaceuticals

Our mission is to improve patients’ lives by identifying, developing and commercializing important specialty pharmaceutical products to address unmet patient needs. We address serious diseases, always with the goal of improving patient care. Keeping patients at the forefront of our mind inspires us to bring innovative and valuable resources to all aspects of our business for the ultimate benefit of the patients in need.

New Horizon Agency Group

New Horizon Agency Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kezar Life Sciences

Kezar co-founder Christopher Kirk, Ph.D. began his work on the unique function of the immunoproteasome at Proteolix in 2005, while working on the compound that would become the successful multiple myeloma drug KYPROLIS™ (carfilzomib). As VP of Research at Onyx Pharmaceuticals, which acquired Proteolix in 2009, Christopher led the efforts to develop the first selective inhibitors of the immunoproteasome and designed multiple studies demonstrating their profound immunomodulatory effects. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential. In 2014, Christopher and Kezar co-founder John Fowler began developing the business plan for Kezar, acting on a longstanding desire to work together and build a world-class company. In 2015, John and Christopher raised $23M and negotiated a worldwide, exclusive license agreement with Amgen for the Onyx immunoproteasome inhibitor patent estate. Now underway, John and Christopher are excited to leverage their complementary skill sets to build Kezar into a leader in small molecule drug development.

HemoShear Therapeutics

We are dedicated to discovering novel biological targets and developing drugs that profoundly improve the lives of people born with rare metabolic defects who are unable to sustain basic biochemical processes necessary for life.

BioDigital

BioDigital is a New York-based biomedical visualization company that is often referred to as being "Google Earth for the Human Body".